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Introduction: Kidney diseases are a global public health problem whose incidence is rapidly growing 
due to a global rise in the aged population and   the increasing prevalence of cardiovascular disease, 
hypertension and diabetes. With the emergence of stem cells as potential therapeutic agents, attempts 
in using them to significantly reduce the burden of these diseases have increased. 
Areas covered: Several types of stem cells have been proven to be likely candidates for treating kidney 
diseases. We discuss in detail the potential use of mesenchymal stem cells in preclinical and clinical 
works, with additional populations that have been studied briefly described. Moreover, we discuss 
current knowledge on endogenous kidney regeneration ability and on the possibility to modulate it using 
chemical and biological agents.  
Expert opinion: Stem cell therapy is a promising new treatment for kidney disease documented in many 
animal studies. Mesenchymal stem cells have emerged as a promising cell type, but their efficacy in 
clinical trials is still controversial. Identification of progenitor cells in the adult kidney is another step 
forward in regenerative medicine, suggesting the repair potential of the adult kidney and the possible 
modulation of renal progenitors in situ using pharmacological approaches. 
 















Kidney diseases are a heterogeneous group of disorders affecting kidney structure and function with 
variable clinical presentation and course.  Kidney diseases can be defined as acute or chronic, depending 
on duration (£  3 vs  >  3 months).  In 2002, a uniform definition and staging system for chronic kidney 
disease (CKD) was launched in the medical community  [1].  The introduction of these guidelines for 
definition and classification of this disease showed that CKD is far more fre-  quent than previously 
appreciated, affecting > 10% of the world’s population [2,3]. The prevalence of CKD increases with age, 
exceeding 20%  in  individuals  older than 60 years and further increasing to 35% in those older than 
70 years [4]. Although multidrug treatment titrated to urinary protein excretion could be successfully 
applied for preventing progression of chronic nephropathies [5], kidney failure, which symptoms are 
usually caused by complications of reduced kidney function, it remains the most serious outcome of 
CKD. For patients in end-stage kidney failure, dialysis or kidney transplant remains the last resort, these 
approaches being however hampered by severe shortage of organ donors, potential organ rejection and 
high medical costs. 
Consequently, new methods to alleviate, cure or prevent renal disease are urgently required to reduce 
the exponentially growing burden due to acute kidney disease and CKD and to improve patients’ 
survival and quality of life. Development of cell-based therapies for human therapeutic application is 
an important emerging challenge. Several potential regenerative cell-based therapies for the treatment 
of renal failure are currently under develop- ment. The first one is the direct application of stem cells 
(SCs) to the diseased kidney. The therapeutic success of this treat- ment depends on the natural 
capabilities of SCs to differenti- ate, organize and integrate into the existing tissues to restore function 
and/or on the capacity of SCs to release renoprotec- tive factors. A wide range of adult SCs and 
progenitor cell types, including bone marrow mesenchymal SCs (MSCs), endothelial progenitor cells 
(EPCs) and renal progenitor cells (RPCs) have been tested in experimental kidney damage models. In 
addition, embryonic SCs (ESCs) and induced pluripotent SCs (iPSCs) have also been recently studied. 
Although findings from a few clinical trials suggested that administration of MSCs to patients suffering 
from CKD is feasible and well tolerated, the effective efficacy of these cells in clinical settings is still 
uncertain and several critical points, namely the choice of the cell type, method of administration and 
timing of delivery, still need to be addressed. Another SC-based strategy is based on the prospective 
design of a therapeutic approach focused on modulation of endogenous kidney regenerative properties 
by conventional chemical and biological agents capable of modulating the activity of resi- dent 
progenitor cells. Indeed, the classical definition of the human kidney as a non-proliferative and non-
regenerative organ has been recently called into question by emerging evidence that the kidney has the 
potential to regenerate itself starting from populations of resident progenitors. In this review, we discuss 
the field of SC-based therapy for kidney disease and focus particularly on the administration of MSCs 
and on the modulation of the endogenous regenerative potential. 
 
2. Which cell type is the best candidate for cell-based therapy of kidney disease? 
 
Multiple different SC types have been investigated for their potential to repair damaged kidney, with 
the not surprising result that the optimal cell type contributing to renal repair still remains disputed. In 
principle, ESCs appear as the best candidate because their pluripotent nature confers them the potential 
to regenerate any cell type in the kidney. However, the pluripotent potential of ESCs also constitutes 
the major obstacle to their safe clinical use due to the possible increased risk of neoplasms arising from 
transplanted cells. To control and reduce this risk, several groups have developed protocols to induce 
differentiation of ESCs into renal lineage using retinoic acid (RA), activin A and bone morphogenic 
proteins [6-9]. The differentiation process is usually relatively inefficient with a low yield of 
differentiated cells; however, recently Mae et al. established a more efficient differentiation protocol of 
human ESCs into intermediate mesoderm [10]. Experimental works demonstrated that it is possible to 
obtain renal cells from ESCs, and that these cells can be differenti- ated into glomerular-like structures 
and integrated into renal proximal tubules in animal models [8-11]. However, the utility of this cell type 




A further significant advancement in cell-based therapy of renal disease is the generation of iPSCs [12]. 
Undifferentiated murine iPSCs attenuate kidney injury in ischemia reperfusion (I/R)-induced acute 
kidney injury (AKI) only when adminis- tered via intra-arterial route, and this beneficial effect is 
mediated by paracrine action [13]. However, as discussed for ESCs, the pluripotent nature of iPSCs raises 
concerns on post-transplantation safety when these cells are administered without pre-differentiation. 
Several studies described protocols to differentiate iPSCs into nephrogenic cells, renal proximal tubular 
cells and podocytes [14-20]. Surprisingly, no beneficial effect on kidney function nor tissue engraftment 
has ever been reported using human pre-differentiated iPSCs in animal models of AKI. On the contrary, 
Imberti et al. recently reported that iPSCs differentiated toward RPCs using an efficient two-step 
differentiation protocol [21], robustly engrafted into damaged tubules and restored renal function and 
structure in a mouse model of cisplatin-induced AKI. In the same experiment, injection of human 
undifferentiated iPSCs, used as control, failed to exert any protective effect on renal function and 
histology. Interestingly, no signs of  inappropriate differentiation and tumor formation by iPSC- derived  
RPCs  were  observed in  the renal  tissues  either at 4 days or 8 weeks after injection [21]. ESCs and 
iPSCs differentiated toward renal phenotypes have been recently demonstrated to generate three-
dimensional kidney structures in vitro [14,22-24]. However, the possibility to obtain functional kidney 
structures has not been directly tested. 
Amniotic fluid-derived SCs (AFSCs) have intermediate characteristics between ESCs and adult SCs [25] 
and have the potential to differentiate in vitro toward renal lineages acquir- ing the expression of 
epithelial and podocyte markers when cultured in appropriate differentiating medium [26,27]. Human 
AFSCs (hAFSCs) injected directly into mouse kidneys with glycerol-induced AKI are  still  present  in  
the  kidney  after  21 days and are specifically located among the tubules where some cells are able to 
commit toward renal differentiation [28]. However, a beneficial effect on serum creatinine and blood  
urea nitrogen (BUN) levels could be observed only when hAFSCs were injected into the kidney on the 
same day of glycerol injection. This effect correlated with a significant increase in proliferative activity 
and with a decreased apopto- sis of tubular epithelial cells [28]. Moreover, hAFSCs exerted 
immunomodulatory effects that appeared to control the local immune response in favor of a tissue 
cytokine and cellular milieu that promotes prevention or resolution of tissue dam-  age [28]. Similar 
results have been reported by Hauser et al.: injection of hAFSCs in an acute tubular  necrosis  mouse  
model induced reduction of creatinine and BUN levels, associated with amelioration of tissue damage, 
reduction of apoptosis and promotion of tubular cell proliferation [29]. Comparison of the regenerative 
potential  of  hAFSCs  with  that of MSCs  in  this  model  of  AKI  demonstrated  that MSCs were 
more efficient in inducing proliferation than hAFSCs, which, in contrast, were more antiapoptotic  [29].  
These beneficial effects are probably mediated through para- crine mechanisms. Indeed, Rota et  al.  
demonstrated  that  in the cisplatin-injured kidney, administration of hAFSCs improved renal function 
and  limited  tubular  damage,  but  they did not differentiate into renal tissue, engrafting predom- inantly 
in the peritubular region without acquiring tubular epithelial markers [30]. Similarly, AFSCs were 
capable of prolonging the animals’ survival, ameliorating the decline in kidney function and delaying 
the progression of glomerular sclerosis and interstitial fibrosis also in mouse  models  of CKD  (Col4a5-
/-  mice,  unilateral  ureteral  obstruction   [UUO]) [31,32]. 
The use of a variety of adult stem or progenitor cells for renal disease, in particular EPCs, RPCs and 
MSCs, has been widely reported. Improvement of renal function after exoge- nous adoptive transfer of 
EPCs has been observed in Adriamycin-induced nephropathy, and in other models of AKI such as the 
renal I/R injury model and the sepsis-induced AKI [33-36]. Administration of EPCs by intravenous 
injection  is limited by the high number of cells that become trapped in the pulmonary vasculature or 
suffer from anoikis. One of the most studied ways to protect administered EPCs and to maximize their 
therapeutic potential is to deliver them embedded in bioengineered scaffolds, such as hyaluronic acid 
(HA) hydrogels [37], implanted either superficially into ears or subcapsularly into kidneys. In comparison 
with intravenous administration, delivery of cells in HA hydrogels provides a microenvironment 
conducive for viability and expansion of embedded cells and protection from circulating cyto- and endo-
toxins and allows mobilization of embedded cells on demand through administration of digestive 
enzymes directly into the implanted HA hydrogels or taking advantage of the intrinsic release of 
hyaluronidase when kidneys are injured [37]. A beneficial effect of EPC injection has also been reported 
in a 5/6 nephrectomy model of CKD [38] and in the UUO model [39]. Indeed, EPCs were successfully 
 
 
incor- porated into the capillary network of the damaged kidney, increasing the number of capillary 
density and alleviating the development of renal fibrosis [39]. 
Potential candidate SCs have been detected in the adult mammalian kidney using different identification 
methods. Using in vivo bromodeoxyuridine labeling, tubular cell populations (label-retaining tubular 
cell), which showed tubu- logenic capacity, integrated into the developing kidney and contributed 
actively to the regeneration of the kidney after ischemic injury were identified in normal adult kidneys 
[40-42]. Alternatively, using the culture of rat kidney or the dissection of single nephron from adult rat 
kidney, researchers demon- strated the existence of highly proliferative cells, especially in S3 segment 
of nephron, which generated cell lines that expressed both immature and mature tubular cell markers. 
These cells engrafted to kidney in rat I/R model, replaced cells in injured tubules and improved renal 
function [43,44]. In addi- tion, mouse kidney progenitor cells, isolated from medulla and papilla 
interstitium, showed characteristics consistent with renal SCs, as demonstrated by their ability to rescue 
renal damage, incorporating in renal tubules and forming new ves- sels after their intrarenal injection 
in mice with ischemic injury [45]. Accordingly, Bussolati et al. described a multipo- tent resident SC 
population in the renal interstitium of human adult kidney, which was capable of clonal expansion in 
vitro and of homing into the injured kidney, and integra- tion in tubules after intravenous injection in 
severely com- bined immunodeficiency mice with glycerol-induced tubular damage [46]. 
In the most recent years a population of RPCs was identi- fied at the urinary pole of Bowman’s capsule 
of adult human kidney. RPCs were identified by co-expression of progenitor markers, 
CD133+CD24+CD106+, in absence of lineage markers. In vitro, these cells displayed typical 
characteristics of adult SCs, such as expression of SC markers, clonogenicity and the potential to 
differentiate toward renal lineages when cultured in appropriate differentiating medium [47]. Injection 
of human RPCs in an acute tubular necrosis mouse model induced reduction of BUN levels, associated 
with ameliora- tion of tissue damage and reduction of fibrosis. These benefi- cial effects were due to 
the engraftment of RPCs into injured tubular structures followed by their differentiation in tubular cells 
[47,48]. Moreover, injection of RPCs into mice with Adriamycin-induced nephropathy reduced 
proteinuria and improved chronic glomerular damage, through their 
engraftment into the glomerular tuft and differentiation into podocytes [49]. 
Mazzinghi et al. described the mechanism responsible for RPCs’ homing to injured kidney [50], 
demonstrating that the homing and the engraftment of RPCs in an acute tubular necrosis mouse model 
are ruled by the CXCR4 -- CXCR7/ stromal cell-derived factor 1 or CXCL12 pathway. Indeed, 
treatment of RPCs before injection with a selective CXCR4 or CXCR7 antagonist induced a dramatic 
reduction in the number of engrafted RPCs. However, although CXCL12-in- duced migration of RPCs 
was only abolished by pretreating cells with an anti-CXCR4 antibody, transendothelial migra- tion was 
mediated by the activity of both CXCR4 and CXCR7 and, last, CXCR7 was essential for RPCs adhesion 
to endothelial cells and for the CXCL12-mediated RPCs survival [50]. 
 
3. Are MSCs the right cell type for renal regeneration? 
 
 
The description of the use of MSCs for SC-based therapy of kidney injury merits a separate section. 
MSCs are undifferen- tiated adult cells defined by adherence to plastic in culture, multipotentiality, 
expression of typical surface markers (CD105, CD73 and CD90) and the absence  of expression of 
hematopoietic lineage markers (CD34, CD45, CD14 or CD11, CD79a or CD19, and human leukocyte 
antigen class II), as suggested by the International Society for Cellular Therapy [51]. MSCs can be 
isolated primarily from bone marrow stroma but it can also be extracted from a variety of tissues, 
including kidney [52-54]. MSCs are  easily  cultured and expanded to obtain clinically useful number of 
cells. Functional properties of MSCs are their capacity to differen- tiate into cells of the mesenchymal 
lineage such as osteocytes, adipocytes and chondrocytes and potentially other cell types and their 
immunomodulatory properties [55,56]. All these properties make MSCs as one of the most promising cell 
type for cell-based therapy in several injured organs/tissues. A large number of studies reported 
evidence that MSCs can promote regenerative responses in the injured kidney, leading to tissue repair 
and improvement of renal function [57-59]. These beneficial effects have been initially attributed to the 
migration of MSCs to the injured kidney, a process mediated by stromal cell-derived factor 1/CXCR4 
 
 
axis [60], and the sub- sequent transdifferentiation of MSCs into  renal-specific cells [61,62]. The possibility 
of direct engraftment of MSCs into the kidney is also supported by the demonstration that MSCs directly 
injected into developing kidney followed by subsequent embryo and organ culture incorporated into 
glo- merulus, tubule and interstitium [63]. However, several other studies showed protection from injury 
by MSCs, but very lit- tle or no tubular incorporation was observed [64-68]. Even if these differences may 
be explained by different injury models and protocols, or by the method used for tracking injected 
MSCs, several data argue against the hypothesis that the beneficial effect of MSCs on renal repair is 
mediated by their engraftment and direct repopulation of the tubule. First, in most studies, the protective 
effect of injected MSCs is observed within 24 -- 48 h, a timing that seems too rapid to be explained by 
transdifferentiation of MSCs into epithelial cells [67]. Second, the numbers of MSC-derived epithelial 
cells appear to be so low (£ 0.1%) that they could not have func- tionally contributed to repairing the 
nephron, at least by direct engraftment [67]. Thus, there is a growing consensus that kidney-protective 
effects of MSCs can be attributed mainly to paracrine and endocrine mechanisms (Table 1). In support 
of this hypothesis are recent data obtained using intravenous injection of nestin+ renal-resident MSCs 
in acute kidney I/R injury; this treatment induced functional improve- ment by significantly decreasing 
the serum creatinine and BUN, and reducing the cell apoptosis, but conditioned medium from nestin+ 
cells could equally protect against ischemic renal failure at least partially through the paracrine factor 
VEGF [68]. 
The immunomodulatory properties of MSCs may play a role in renoprotection, because inflammation 
is of great importance in the pathophysiology of AKI. Allogeneic MSCs, indeed, express low levels of 
MHC class I and class II molecules, do not express major costimulatory molecules such as CD40, CD80 
and CD86 and inhibit dendritic cell alloantigen-induced differentiation and activation [69]. More- over, 
MSCs produce prostaglandin E2 that modulates T-cell function, decreasing secretion of 
proinflammatory cytokines TNF-a, and IFN-g and increasing secretion of suppressive and tolerance-
promoting cytokines IL-10 [69]. In accordance, high levels of anti-inflammatory cytokines have been 
found in kidney extracts from MSC-treated animals after I/R  injury [70]. Prostaglandin E2 released by 
MSCs also acts on monocytes and/or macrophages through the prostaglandin EP2 and EP4 receptors 
increasing their IL-10 production [71]. Through this mechanism, intravenous injection of MSCs 
beneficially modulated the response of the host immune sys- tem to sepsis and improved survival in a 
mouse model of cecal ligation and puncture [71]. Exposure of MSCs to proinflam- matory stimuli 
promotes the immunosuppressive activity of MSCs, resulting in protection from natural killer-mediated 
cytolysis, inhibition of IL-2-induced natural killer prolifera- tion, induction of hepatocyte growth factor 
and TGF-b secre- tion and induction of indoleamine 2,3-dioxygenase (Table 1) 
[56,72-74]. 
MSCs can secrete a broad repertoire of growth factors and cytokines with considerable positive 
potential for the treatment of kidney disease: G-CSF, SC factor, leukemia- inhibitory factor, 
macrophage-colony stimulating factor, IL-6 and IL-11, VEGF, basic fibroblast growth factor, 
monocyte-chemoattractant protein-1, hepatocyte growth fac- tor and IGF-1 [75,76]. Some of these 
molecules act on epithelial cells promoting proliferation, others promote angiogenesis and exert 
vasculoprotective actions [77], yet others are anti- inflammatory and antiapoptotic, but all can protect the 
kidney from further injury and accelerate repair. It is of inter- est that MSCs also confer protection from 
I/R injury when injected intraperitoneally, that is, in absence of MSCs homing to the kidney [78]. In this 
case, the beneficial effect must be attributed to the low systemic concentrations of factors released from 
extrarenal MSCs. 
MSCs have been tested successfully in experimental models of CKD. A single intravenous injection of 
MSCs prevented renal damage in streptozotocin-induced type 1 diabetes in C57BL/6 mice, and treated 
animals showed histologically normal glomeruli and a significant decrease in  albumin- uria [79]. Similar 
results have been obtained in not obese diabetic/severe combined immunodeficiency mice: in this 
model, intracardiac infusion of human MSCs decreased mesangial thickening and macrophage 
infiltration with a few injected MSCs differentiating into glomerular endothelial cells [80]. MSCs 
injected in rats with modified 5/6 nephrec- tomy persisted within the kidney 1 day after nephrectomy 
[81], but no significant differences in BUN and creatinine concen- tration were observed between the 
MSCs group and the con- trol group. However, proteinuria in the MSCs group was lower than that in 
the control group. Interestingly, VEGF lev- els were substantially higher in MSC-treated animals 1 
 
 
month after MSC injection, thus suggesting that the beneficial effects were mediated by secretion of 
paracrine factors [81]. This con- clusion is also supported by recent data in rats subjected to UUO: indeed, 
the intravenous administration  of  both MSCs and MSC-conditioned medium improved fibrosis 
progression [82]. Intrarenal infusion of MSCs isolated from subcutaneous adipose tissue protected the 
stenotic kidney despite sustained hypertension [83]. Remarkably, MSCs also attenuated renal 
inflammation, endoplasmic reticulum stress and apoptosis through cell-contact-mediated mechanisms. 
Furthermore, MSCs improved renal function and structure after renal revascularization and reduced 
inflammation, oxida- tive stress, apoptosis, microvascular remodeling and fibrosis in the stenotic kidney 
[84]. Recently, Papadimou et al. found that human MSCs could be reprogrammed into renal proximal 
tubular cells by exposure to HK-2-cell-free extracts. These reprogrammed cells acquired an antigenic 
profile and func- tional properties of  proximal  tubular-like  epithelial  cells  in vitro, integrated into 
developing nephrons ex vivo and protected mice from AKI [85]. 
All  these   preclinical  murine  models  offer  the   proof   of concept that the use of MSCs in the 
management of AKI is rational and feasible. However, further studies are required to meet the quality 
and safety criteria before applying MSC administration in clinical studies. We need to validate different 
models and standardize different protocols of MSC application to facilitate the comparison among 
results. Indeed, several issues have to be solved, first the better route of MSCs administration. To this 
aim, studies should be focused on the direct comparison of the administration through the tail vein, 
carotid artery or renal artery in different animal models. In rat model of renal I/R injury, authors 
observed that 1 × 10(5) MSCs injected through renal  artery produces the most dramatic improvement 
in renal function and morphology [86]. Second, MSCs from different sources (bone marrow, adipose 
tissue, kidney) have to be compared in terms of accessibility, yield and clinical efficacy [87]. Another 
point to fix is the use of autologous or allogeneic cells. T€ogel et al. [88]  investigated the long-term 
outcome of treatment after injecting autologous or allogeneic bone marrow MSCs in a rat model of 
AKI. Identical doses of autologous MSCs were more effective than allogeneic, but both autologous and 
allogeneic cells were able to reduce late renal fibrosis and loss of renal function in surviving animals. 
However, age or systemic disease may influence and decrease the regenerative potential of autologous 
MSCs, as demon- strated by Klinkhammer et al. who investigated the negative effects  of  CKD  on  
MSCs’  function  and  concluded  that CKD/uremia lead to a sustained loss of in vitro and in vivo 
functionality in MSCs, likely due to premature cellular senes- cence [89]. This finding raises doubts on 
the possibility of obtaining beneficial effects from autologous transplantation in CKD patients. 
Recently, a systematic review and meta-analysis to evaluate the efficacy of cell-based therapy in 
preclinical studies of  CKD, and determined factors affecting cell-based therapy efficacy in order to 
guide future clinical trials, has been published [90]. Analysis of 71 articles with difference in the selection 
and preparation of cells, administration route and choice of disease model and model species showed 
that cell- based therapy reduced the development and progression of experimental CKD. This was most 
evident when urinary pro- teins and urea levels were analyzed. Sub-analysis showed that cell type (bone 
marrow-derived progenitors and mesenchymal stromal cells being most effective) and administration 
route (intravenous or renal artery injection) were significant predic- tors of therapeutic efficacy. On the 
contrary, the timing of therapy in relation to clinical manifestation of disease, and cell origin and dose, 
did not influence the efficacy of the treat- ment [90]. The differences observed in the functional efficacy 
of cell-based therapy in CKD appeared to be model-depen- dent, thus reflecting the different 
pathogenesis of CKD when initiated by subtotal nephrectomy versus, for example, toxic injury, whereas 
for structural efficacy, most models showed improvement of all outcome variables, perhaps reflecting 
the common pathway to end-stage kidney failure. Such differences might also be relevant when 
designing cell therapy studies in specific patient populations. 
 
4. MSCs in human clinical trials of cell-based therapy for kidney repair 
 
The interesting results obtained in preclinical studies of MSC administration in kidney diseases 
prompted to the translation of MSC-based treatments in humans. The clinical studies are still limited. 
A Phase I clinical trial (NCT00733876) has been performed to determine if the administration of 
allogeneic MSCs at defined doses is safe in patients who are at high risk of developing AKI after 
undergoing on-pump cardiac sur- gery. Preliminary data on the first five treated patients showed that 
 
 
kidney function is preserved up to 16 months and that  none of the patients required dialysis [91].  On  
the  contrary, 20% of case controls developed acute renal failure. The length of hospital stay and 
readmission rates in study patients were reduced by 40%. No therapy-related adverse  events  were  
noted in these patients [91,92]. The Phase I explorative  study (NCT 01275612) on three patients with 
acute renal failure induced by cisplatin treatment for solid organ cancers has demonstrated   that   
intravenous    infusion    of    autologous ex vivo-expanded MSCs improves  renal  function  and  that  
the procedure is safe. The Phase II trial NCT 01602328 enrolled subjects  who  experienced  kidney  
injury  (defined  by a creatinine rise ‡ 0.5 mg/dl) within 48 h of cardiac surgery to assess safety and 
efficacy of single  administration  of  human MSCs. More than  150  subjects  were  enrolled  and  the 
trial was terminated because no beneficial effects were observed [93]. However, the use of a rise in 
creatinine provides late information on the possibility of evolving AKI; a more  specific and early 
biomarker, such as kidney  injury  molecule-1, neutrophil gelatinase-associated  lipocalin  or IL-18 
would be more appropriate to diagnose AKI and thus allow to start the treatment earlier with a higher 
probability     of success. 
A Phase I, single-group assignment, open-label study (NCT01840540) is recruiting participants to 
determine the safety and toxicity of intra-arterial-infused autologous adipose-derived mesenchymal 
stromal (stem) cells in the treat- ment of 15 patients with atherosclerotic renal artery stenosis affecting 
one or both kidneys and serum creatinine < 2.5 mg/100 ml. 
The preliminary results presently available confirm that MSC treatment is safe, but other data are 
required to evaluate clinical benefit and the effects observed in clinical trials must be critically analyzed 
to understand when negative results could be due to an inadequately designed trial. Moreover, the long-
term safety of MSC treatment must be verified in view of the preclinical data published by Kunter et 
al. [94]. The authors injected high number of MSCs  intrarenally  into rats in a model of 
glomerulonephritis and reported a beneficial therapeutic effect on day 60, but ~ 20% of the glomeruli 
of MSC-treated rats contained large adipocytes derived from maldifferentiation of MSCs with 
pronounced surrounding fibrosis. 
 
5. Does the endogenous regenerative capacity of the kidney exist and how can it be modulated? 
 
Exciting concepts have emerged over the past decade on the regenerative capacity of the kidney, and 
this field now appears able to advance rapidly showing some fundamental principles of kidney 
regenerative biology. One of the most interesting 
recent finding was the indisputable demonstration that the kidneys of lower vertebrates such as the 
elasmobranch skate and zebrafish could  generate  entire  new  nephrons  after injury [95,96], thereby 
demonstrating the existence of adult progenitors capable of kidney regeneration. In contrast  to lower 
vertebrates, the mammalian kidney shows a limited capacity for regeneration. Indeed, a partial 
nephrectomy can induce the formation of new nephrons  during  development, but this capacity seems 
to be lost shortly after birth [97]. How- ever, the knowledge of how the adult kidney repairs itself is a 
remarkable promise and this is the reason why many debates, regarding the identification of key cellular 
players in renal regeneration, characterize this field of intense research. How- ever, even if several 
recent lines of evidence confirmed that parietal epithelial cells (PECs) of Bowman capsule may serve  
as progenitor cells for podocytes  during  kidney  growth  [98] and may have a role in glomerular repair 
by replacing lost podocytes [49,97,99], controversial data in adult mouse kidney rather suggested that 
PECs’ activation is harmful and drives generation of hyperplastic intraglomerular cellular lesions 
leading to nephron degeneration [100]. In addition, other cell types such as renin cells of the  
juxtaglomerular  apparatus  have been reported as a source [101] of both PECs and podo- cytes in a murine 
model of focal segmental glomerulosclerosis (FSGS). However, Starke et al. demonstrated that renin 
line- age cells represent a major source for reconstitution of the intraglomerular mesangial cells and not 
endothelial, podocyte or PECs after injury [102]. A similar debate regards the regenerative capacity of 
the tubular compartment,  which  shows evidence of a certain proliferation responsible of cellu- lar 
repair and tissue remodeling, causing a quick recovery of kidney function in response to AKI. Some 
researchers pro- posed that fully differentiated tubular cells would transiently undergo a cycle of 
dedifferentiation, proliferation and, ultimately,  redifferentiation  [103-106],  whereas   others   argued on 
the existence of an intratubular progenitor population  which, poised in a quiescent state, would re-enter 
 
 
the cell cycle with the aim of replacing tubular cells [41,44,97]. Resolution of these debates is essential for 
developing new therapeutic strat- egies to prevent AKI, as well as CKD. In the  most recent years, the 
existence of a renal progenitor system  consisting    of a heterogeneous population of RPCs with 
different com- mitment in adult human kidney has been demonstrated [47-49]   and has been proposed as 
the main source to replace podocyte and/or tubular cell lost during an insult, at least in humans [97]. For 
this reason, it is becoming mandatory to  clarify  which tools we could use to manage the regenerative 
potential and how to enhance the endogenous regenerative processes to achieve kidney repair. 
Nowadays, the existence of a renal progenitor system seems to be the most hopeful discovery to  set up 
new potential therapeutic treatments for kidney disease and to identify new targets in order to accelerate 
their  regenerative response. 
 
  
  5.1 How current pharmacological treatments can enhance kidney regeneration 
The clinical benefits of  the  current  pharmacological treatments such as corticosteroids and inhibitors 
of the renin-angiotensin (Ang) system such as ACE inhibitors (ACEis) and Ang II type I receptor  
blockers (ARBs) to  halt the progression of CKD are well described. The study of molecular 
mechanisms of glucocorticoids and ACE inhibition has increased knowledge on the action of these 
molecules, clarifying their benefic role in the treatment of kidney disease. Of note, several evidences 
have demonstrated that these mol- ecules can be, surprisingly, a selective way to potentiate the 
regeneration of the glomerulus by increasing the differentia- tion of RPCs toward podocyte lineage at 
least in adult mice  and rats [107,108]. Indeed, a recent study demonstrates that prednisone administration 
in mice with  experimental  FSGS has a dual biological effect on both podocytes and RPCs. Of note, 
this effect was either the reduction of the magnitude of podocyte apoptosis or the increase of podocyte 
markers acquired by RPCs, determining a final enhanced number of podocytes that correlated directly 
with decreased glomerulo- sclerosis and reduced proteinuria [107].  Moreover, animal models of non-
diabetic and diabetic nephropathy have clearly shown that treatment with ACEis and ARBs or their 
combi- nation not only prevented progressive renal damage but also promoted the regression of 
glomerulosclerosis and vascular lesions [109]. By performing three-dimensional analysis to estimate the 
volume of glomerular tuft, a reduction in exten- siveness of sclerotic lesions and regeneration of new 
normal capillary tuft was demonstrated, suggesting  that  remodeling of glomerular architecture is  
possible,  and  that  some  forms of regeneration can occur. Based on these findings, one possi- ble 
mechanism that elucidated the effects observed after ACEi treatment could involve  the restoration  of 
podocyte number  by increasing their number per capillary tuft [108]. The hypo- thetical population 
responsible for the regression of glomeru- lar lesions was considered to be a subset of PEC in Bowman’s 
capsule of rat kidney, which was characterized by the expression of the marker Neural cell adhesion 
molecule (NCAM). These cells showed outstanding ability to acquire phenotypic features of 
differentiated podocytes in vitro [110], as also reported for the human RPCs, suggesting their  
determinant role in the restoration of podocyte number in vivo. Moreover, another effect observed 
following treatment with ACEi was   the reduction of PEC proliferation in the formation of cres- cents, 
preventing the evolution toward  glomerulosclerosis,  and demonstrating that this treatment can 
reestablish  a  nor- mal glomerular architecture [110]. Mechanisms responsible for  RPCs’  proliferation  
seem  to  involve  the  expression  of Ang II receptor, AT1, which is upregulated in the hyperplastic 
lesions [111]. These results suggest a crucial  contribution  of Ang II/AT1 receptor pathway in promoting 
abnormal RPCs’ migration and  proliferation  in  proliferative  diseases  [109,111] and give another 
explanation to the beneficial effects observed 
after ARBs treatment. Indeed, ACEi therapy given to a patient with crescentic glomerulonephritis 
limited progenitor cell proliferation and normalized AT1 receptor expression on RPCs, concomitant 
with the regression of hyperplastic lesions. However, although treatment of glomerular diseases with 
ACEis or ARBs slows the progression of kidney disease, the mechanisms mediating their 
renoprotective effects are only partially known [112]. 
 
5.2 Future challenges to enhance endogenous kidney regeneration 
Further to drugs acting on immune system and on renin-Ang system, several other compounds were 
proposed to target glo- merulosclerosis by improving podocyte  regeneration  by RPCs. Such drugs 
 
 
include chemokines or chemokine receptor antagonists [113], retinoids [114], Notch inhibitors [115], b-cate- 
nin/Wnt molecules [116]  and  IFNs  [117].  The  dual  antagonism of the  chemokine  ligand  monocyte-
chemoattractant  protein- 1 or CCL2 and CXCL12 showed additive and synergistic pro- tective effects 
on the progression of diabetic nephropathy [113], combining the protective effect on CCL2-mediated 
glomeru-  lar leukocyte recruitment with  that  on  CXCL12-mediated  loss of podocytes. In vitro studies 
demonstrated that the effect of CXCL12 blockade increased podocyte number and neph-  rin or podocin 
mRNA expression, enhancing RPC differenti- ation toward the podocyte lineage, and thus, enhancing 
podocyte regeneration [113]. The rationale of  the clinical  ben- efit of CXCL12 blockade also resides in 
direct evidence about the contribution of CXCR4/CXCL12 pathways to the abnor- mal behavior of 
RPCs in proliferative  diseases  [111].  Indeed, the interaction of CXCR4, expressed by PECs, with its 
ligand CXCL12, produced by podocytes, triggers and enhances RPCs  proliferation  in  the  Bowman’s  
capsule,  leading  to hyperplasia. These findings promote CXCL12 blockade as a novel strategy to more 
efficiently prevent crescentic lesions  and glomerulosclerosis and to foster the regenerative capacity of 
RPCs. 
Retinoids can be added to the number of molecules with a renoprotective function that were widely 
investigated. How- ever, the potential role of these molecules in promoting kidney regeneration has 
been unveiled only recently. RA represents the key inducer of RPCs differentiation toward the podocyte 
lineage in vitro, allowing the acquisition of spe- cific podocyte markers and proper features of podocytes 
[114]. However, exposure to albumin, which represents the specific carrier of RA, can impair RPCs 
differentiation into podocytes by sequestering RA. In agreement with in vitro results, block- ing 
endogenous RA synthesis in experimental FSGS, markedly increased albuminuria and mortality, 
whereas the exogenous administration of RA neutralizing the sequestering activity of albumin allowed 
the regenerative response of RPCs, determining an increase in podocyte number and the improvement 
of renal function [114]. These data suggest that endogenous RA is essential for podocyte number 
maintenance and the presence of even a small amount of albumin within the Bowman’s space can be 
detrimental for an appropriate regenerative process to occur [114]. However, once podocyte damage is 
severe and leads to a progressive increase of protein- uria  within  the  Bowman’s  space,  RPCs’  
response  to  RA  is impaired, causing a failure of differentiation into podocytes, and an aberrant RPC 
proliferation that generates hyperplastic glomerular lesions [100]. Recently, new pathways such as Notch 
and b-catenin/Wnt signaling involved in growth/ differentiation of RPCs toward the podocyte lineage 
were investigated, providing evidence that a regulated balance between podocyte loss and regeneration 
by RPCs influences the severity of glomerular disorders. In vitro experiments have shown that Notch 
activation in human RPCs leads to entry into the S-phase of the cell cycle and successive cell divi- sion, 
whereas its downregulation is essential for RPC differen- tiation into podocytes [115]. Accordingly, 
inhibition of Notch signaling throughout the regenerative phases leads to a worsened podocyte loss 
resulting in glomerulosclerosis and a worsening of the albuminuria  in  a  mouse  model  of  FSGS [115]. 
Conditional b-catenin  knockout mice,  in  which a Wnt down-target has been deleted, form abnormal 
kidneys and have reduced renal function. Tracing nephrogenesis in embryonic knockout mice revealed 
that the Wnt pathway drives the differentiation of RPCs into podocytes in the pari- etal layer of the S-
shaped body by direct lineage switch [116]. Furthermore, recent evidence demonstrates the distinct effects 
of IFN-a and IFN-b on podocytes and RPCs in vitro and in an Adriamycin-induced nephropathy mouse 
model. Of note, IFN-b specifically promoted podocyte loss by inducing mitotic catastrophe of 
podocytes, IFN-a affected proliferation and migration of RPCs in vitro and in vivo, and both IFNs 
impaired the differentiation of RPCs into mature podocytes in vitro [117]. Further studies are needed 
to determine the  role and contribution of specific signaling pathways in the balance between podocytes 
loss and the physiologic regenera- tive capacity of RPCs. The identification of novel targets will open 
the previously unthinkable possibility that in patients with glomerular disorders this balance might be 




SC therapy is potentially a promising new treatment for kid- ney disease. The benefit of cell therapy 
has been documented  in many animal studies [90-92], and MSCs have emerged as a promising cell type, 
due to the allogeneic potential of trans- plantation, the ability to undergo in vivo renal differentiation 
 
 
(albeit at low levels)  and  the  paracrine  mechanisms  of  action [57-70,77-87]. Potentiating MSCs migration, 
engraftment, survival and paracrine effects using preconditioning or genetic modification strategies 
could optimize the beneficial effect of this kind of therapy [118]. In clinical trials no major adverse  effect 
has been attributed to the injection of MSCs [91-93]. However, the efficacy of these cells is still 
controversial at least 
in part due to differences in protocols used such as the num- ber of administered cells and the time of 
administration. Other important aspects that can influence the therapeutic potential of MSCs are donor 
age and functional abnormality of MSCs isolated from patients with renal diseases. Moreover, there is 
also a need to carry out appropriately designed exper- imental studies to verify the long-term safety of 
these therapies and to examine the risks of fibrosis, maldifferentiation or malignancy and only the 
results of larger, well powered rigor- ously designed clinical trials will determine the real clinical 
efficacy of MSC therapy in kidney diseases. 
In our opinion, a progenitor cell of a particular tissue is perhaps the right source to treat tissue-specific 
diseases. This kind of cell can be obtained through differentiation of ESCs or iPSCs. However, research 
toward the kidney regeneration strategy using ESCs and iPSCs is in its infancy. Continued 
efforts are necessary for the establishment of step-by-step differentiation protocols directing the 
pluripotent SCs first  to form intermediate mesoderm, then renal progenitors, followed by the formation 
of mature, functional renal cells and to try to overcome the current problems with these cell types: 
heterogeneity in the differentiation potential,  interline variability and low frequency and inefficient 
transduction of iPSCs. 
Adult kidney-specific stem/progenitor cells are an alterna- tive approach of SC-based therapy in renal 
disease. However, at present, the possible application of these cells cannot be envisaged, for several 
reasons. RPCs are not easily accessible and need to follow an ex vivo expansion process before 
implantation; moreover, age or CKD may influence and decrease the regenerative potential of 
autologous RPCs; thus, we need to verify the compatibility among patients to use allogeneic RPCs. 
In any case, identification of progenitor cells in the adult kidney was another step forward in 
regenerative medicine, suggesting that the repair potential of the adult kidney also exists in mammals. 
Targeting this function in situ using pharmacological approaches or targeting potential pathways in 
order to accelerate the regenerative response may be a near-term application of regenerative approaches 
because they are amenable to traditional drug and biologic therapies. Experimental data suggest that 
reconstitution of functional tissue by renal progenitors could theoretically be confined to the early phase 
of the disease, becoming limited as the damage increases, as we demonstrated for podocyte 
replacement,  which was completely abolished when albumin within the Bowman’s space increases 
even slightly, sequestering RA, the key  molecule  for  RPC  differentiation  toward  the  podo-  cyte 
[114]. This phenomenon is not ineluctable, as underlined    by the occurrence of glomerular regeneration 
when protein- lowering drugs such as ACEis are used, and can be even phar- macologically enhanced, 
turning failure  into  success  [108-110]. On the contrary, in the advanced phases of the disease, the 
endogenous regeneration  of  the  podocytes  operated  by  RPCs seems unable to correctly and 
successfully replace a sig- nificant loss of cells, but RPCs rather chaotically  proliferate and migrate, 
leading to lesion formation and subsequent sclerosis [111,114,118]. The enhancement of the repair 
process operated by RPCs toward regeneration could be obtained through the delivery of drugs [107-
110] or targeting  other  puta- tive renoprotective pathways, such as chemokine receptor antagonists, 
Notch, Wnt and IFNs [113-117]. Targeting of these pathways, however, might exert negative effects 
on other renal and extrarenal cell types. Thus, future studies will likely identify more candidate 
signaling pathways implicated in RPCs’  maintenance,  regulation  and  response  after  injury. Genetic 
lineage-tracing approaches will facilitate this work improving progenitor cell characterization and 
enabling  us to examine their differentiation potential in vivo and their response to pharmacological 
agents. These combined efforts will favor the translation of experimental results into clinical practice. 
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Table 1. Indirect mechanisms of MSCs-mediated renoprotection and repair of kidney damage. 
 
Target cells Effects Refs. 
 
Trophic actions 
Secretion of bioactive factors: 
SDF-1, VEGF, HGF, G-CSF, stem cell 
factor, leukemia-inhibitory factor, 
macrophage-colony stimulating factor, IL-
















Release of microvesicles or 
exosomes containing: 











Release of soluble factors: 
PGE-2, TGF-b, HGF, IL-10, nitric oxide, 
soluble TNF-receptor 1 
Dendritic cells Inhibition of differentiation and activation [56,69-75] 
T cells Inhibition of proliferation, activation and release of TNF-a and IFN-g 
increased secretion of suppressive cytokine IL-10 
NK cells Inhibition of proliferation 
B cells Inhibition of proliferation, antibody production and chemotaxis 
Treg Increase the number of Tregs Neutrophils Reduce infiltration 
 
 
HGF: Hepatocyte growth factor; MSC: Mesenchymal 
stem cell; NK: Natural killer; SDF-1: Stromal cell-





Table 2. Endogenous renal regeneration can be modulated targeting both RPC differentiation and/or proliferation. 
 
Effect on Treatment Observation Model Ref. 
 
Differentiation  Corticosteroids Increase  of podocyte number Animal  model of FSGS [107] 
ACE inhibitors Increase of podocyte number Animal models of non-diabetic and 
diabetic nephropathy MWF rat 
Human proliferative glomerulonephritis 
[108,110] 
CXCL12 antagonist Increase of podocyte number Animal model of diabetic nephropathy [113] 
Upregulation of nephrin and podocin mRNA expression by RPCs 
Retinoic acid Acquisition of specific podocyte markers and proper 
features of podocytes by RPCs 
Primary culture of human RPCs 
 
Primary culture of human RPCs [114] 
Increase of podocyte number Animal model of Adriamycin nephropathy 
DAPT (Notch inhibitor)   Differentiation of RPCs into podocytes    Primary culture of human RPCs [115] 
Animal model of FSGS 
Conditional b-catenin knockout Switch in lineage differentiation 
of RPCs toward a podocyte-like 
cell fate 
b-catenin--deficient mice [116] 
IFN-a; IFN-b Suppression of RPC differentiation into 
podocytes 
Reduction of podocyte number 
Primary culture of human RPCs [117] Animal model 
of adriamycin-induced nephropathy 
Proliferation ACE inhibitors Reduction of RPCs proliferation Animal models of non-diabetic and 
diabetic nephropathy MWF rat 
Human proliferative glomerulonephritis 
[110] 
Angiotensin II type I receptor 
blockers 
Reduction of RPCs proliferation Animal models of non-diabetic and 
diabetic nephropathy MWF rat 
Human proliferative glomerulonephritis 
[111] 
IFN-a Reduction of RPCs proliferation Animal model of adriamycin-induced 
nephropathy 




DAPT: N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; FSGS: Focal segmental glomerulosclerosis; 




. Stem cell-based therapy for kidney diseases is an exciting research area. 
. Embryonic stem cells, induced pluripotent stem cells, amniotic fluid-derived 
stem cells, endothelial progenitor cells, mesenchymal stem cells (MSCs) and 
renal progenitor cells (RPCs) are some of the cell types that have been 
associated with a benefit in several animal models of kidney disease. 
. MSCs have emerged as a promising cell type for treatment of kidney 
disease. 
. The benefit of MSCs is mediated mainly through paracrine and 
immunomodulatory mechanisms rather than engraftment and differentiation. 
. MSCs’ delivery to human subjects in clinical trial settings  is safe but the efficacy 
of these cells is still controversial. 
. RPCs are present within the kidney and are involved in renal repair. 
. The authors propose a therapeutic strategy based on the enhancement of 
endogenous kidney regenerative properties by conventional chemical and 
 
 
 
